Clinical Trials

Melanoma

NCT04061980 2026-04-13

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

24 enrolled

Head & Neck

Thyroid Neoplasms

NCT05308446 2026-04-13

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

84 enrolled

Colonic Neoplasms, Rectal Neoplasms

NCT06102902 2026-04-13

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Phase 1 Recruiting

30 enrolled

Colorectal Neoplasms

NCT07022457 2026-04-13

UK-EnBiRiM

Active not recruiting

50 enrolled

Phase 3 Active not recruiting

Melanoma

NCT04657991 2026-04-07

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

257 enrolled

Melanoma, Skin Neoplasms

NCT05203172 2026-04-07

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Phase 4 Recruiting

46 enrolled

Other solid neoplasm

Solid Tumors

NCT05217446 2026-04-07

SEAMARK

107 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04221438 2026-04-01

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Phase 2 Terminated

3 enrolled 11 charts

Other hematologic neoplasm

Lymphatic Metastasis, Melanoma

NCT04324112 2026-03-31

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Phase 2 Recruiting

45 enrolled

Leukemia, Hairy Cell

NCT04074096 2026-03-25

BEPCOME-MB

10 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT05039177 2026-03-25

HERKULES-3

Phase 1/2 Completed

101 enrolled

98 enrolled 18 charts 2 FDA

Digestive System Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03915951 2026-03-24

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Phase 2 Completed

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT05985954 2026-03-12

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

Phase 1 Recruiting

27 enrolled

Colorectal Neoplasms

NCT05926960 2026-03-09

PORTSIDE

Phase 2 Terminated

38 enrolled

Phase EARLY_PHASE1 Recruiting

Melanoma, Skin Neoplasms

NCT04741997 2026-03-02

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

50 enrolled

921 enrolled 48 charts 2 FDA

Melanoma

NCT01909453 2026-02-27

COLUMBUS

Phase 3 Completed

Phase EARLY_PHASE1 Not yet recruiting

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT07318389 2026-02-27

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

100 enrolled

Colorectal Neoplasms

NCT04903119 2026-02-13

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Phase 1 Recruiting

30 enrolled

Phase EARLY_PHASE1 Active not recruiting

Melanoma

NCT03543969 2026-02-05

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

14 enrolled

Phase 2/3 Active not recruiting

Melanoma, Skin Neoplasms

NCT05710406 2026-01-26

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

1 enrolled